Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Launches EPGrade MCTs

China’s Leading Specialty Pharma Supplier Delivers Domestic Alternative to Imported High-Grade Lipid Excipients

Guangzhou, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a global leader in high-end pharmaceutical lipid excipients, today officially launched its European Pharmacopoeia (EP)-grade Medium Chain Triglycerides (MCTs) API series. This new product is designed to address the core pain point of the pharmaceutical industry’s reliance on imported high-grade lipid excipients, featuring three key advantages: domestic independent control, green production processes, and global compliance certifications. With this launch, the company aims to break long-term foreign monopolies, enhance the security of China’s pharmaceutical industry chain, and further expand its global footprint in the pharmaceutical lipid market. The EP-grade MCTs series is now available for global pre-order and has entered mass production with worldwide shipping initiated .

Core Technological Breakthroughs & Product Highlights

Domestic Independent Control: The company successfully developed the first domestic EP-grade MCTs, boosting the localization rate of high-end pharmaceutical lipid excipients from 10% to 90% and breaking long-term foreign monopolies in this sector .

Green Production Processes: It pioneered an integrated green technology combining supercritical CO₂ extraction, membrane separation, and chromatographic separation, replacing traditional polluting processes and meeting national green factory standards .

High Purity & Compliance: The product achieves a purity of over 99%, strictly adhering to EP standards to meet the quality requirements of global pharmaceutical enterprises for high-end lipid excipients .

Global Compliance & Certifications

To meet global market access requirements, the new EP-grade MCTs series has obtained multiple international authoritative certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. It complies with regulatory requirements in major global markets such as the EU, North America, and Asia-Pacific, and can be widely used in the production of chemical drugs, biologics, traditional Chinese medicines, and high-end preparations .

Supply Information & Customized Services

The EP-grade MCTs series is now available for global pre-order through the official website (http://byshanhanfang.com/), authorized global distributors, and international exhibition channels, with mass production and worldwide shipping already initiated . In addition to standard products, the company provides customized processing services for global pharmaceutical enterprises and health product manufacturers to meet diverse needs of different dosage forms and production processes .

Authoritative Quotes

"The launch of EP-grade MCTs marks another key breakthrough for us in the high-end pharmaceutical lipid excipients sector, providing reliable domestic alternatives for global customers," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "We will continue to focus on tackling 'bottleneck' technologies and promoting the technological self-reliance of China's pharmaceutical industry" .

Industry Background & Corporate Strategy

Driven by the growing global demand for high-end pharmaceutical preparations, the global pharmaceutical lipid excipients market maintains steady growth. As a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.'s launch of the EP-grade MCTs series responds to the global market's demand for domestic high-end pharmaceutical excipients, strengthening its leading position in the global pharmaceutical lipid sector .

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to deepen its presence in the high-end pharmaceutical lipid excipients field, increase R&D investment, launch more innovative products meeting international standards, and improve its global sales and service network to provide localized support for customers in more countries and regions .

Company Profile

Founded in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a core modern pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings (GPHL) Group, focusing on the R&D, production, and sales of high-end pharmaceutical lipid excipients, characteristic anti-tumor APIs, and Ganoderma health products . It owns China's only national engineering research center for traditional Chinese medicine engineering technology and multiple provincial-level R&D platforms. As of 2025, the company holds over 240 patents, with products sold in more than 30 countries and regions . As a national-level "Little Giant" enterprise and national green factory, the company is committed to solving "bottleneck" problems in the pharmaceutical industry chain and safeguarding human health . For more information, visit http://byshanhanfang.com/.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.